EUVIMEDEUVIMED entdecken
Crossref

Structure-Guided Design and Synthesis of Pyridinone-Based Selective Bromodomain and Extra-Terminal Domain (BET)-First Bromodomain (BD1) Inhibitors

Yangfeng Li iD, Zhengnan Shen, Kiira Ratia, Jiong Zhao, Fei Huang, Oleksii Dubrovyskyii, Divakar Indukuri, Jiqiang Fu, Omar Lozano Ramos, Gregory R J Thatcher iD, Rui Xiong iD

Journal of Medicinal Chemistry · 2024

DOI: 10.1021/acs.jmedchem.3c01837 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Yangfeng Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: UICentre (Drug Discovery@UIC), University of Illinois at Chicago, 833 S Wood Street, Chicago, Illinois 60612, United States. Hauptthemen laut MEDLINE: Transcription Factors, Nuclear Proteins. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: NCRR NIH HHS, NIAID NIH HHS, Chicago Biomedical Consortium.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The bromodomain and extra-terminal domain (BET) proteins are epigenetic readers, regulating transcription via two highly homologous tandem bromodomains, BD1 and BD2. Clinical development of nonselective pan-BD BET inhibitors has been challenging, partly due to dose-limiting side effects such as thrombocytopenia. This has prompted the push for domain-selective BET inhibitors to achieve a more favorable therapeutic window. We report a structure-guided drug design campaign that led to the development of a potent BD1-selective BET inhibitor, 33 (XL-126), with a Kd of 8.9 nM and 185-fold BD1/BD2 selectivity. The high selectivity was first assayed by SPR, validated by a secondary time-resolved fluorescence energy transfer assay, and further corroborated by BROMOscan (∼57-373 fold selectivity). The cocrystal of 33 with BRD4 BD1 and BD2 demonstrates the source of selectivity: repulsion with His437 and lost binding with the leucine clamp. Notably, the BD1 selectivity of BET inhibitor 33 leads to both the preservation of platelets and potent anti-inflammatory efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transcription FactorsNuclear ProteinsProtein DomainsAnti-Inflammatory AgentsPyridonesCell Cycle Proteins

Substanzen

Transcription FactorsNuclear ProteinsAnti-Inflammatory AgentsPyridonesCell Cycle Proteins

Autor:innen und Institutionen

  • UICentre (Drug Discovery@UIC), University of Illinois at Chicago, 833 S Wood Street, Chicago, Illinois 60612, United States.
  • Department of Pharmaceutical Sciences, University of Illinois College of Pharmacy, University of Illinois at Chicago, 833 S Wood Street, Chicago, Illinois 60612, United States.
  • Research Resources Center, University of Illinois at Chicago, Chicago, Illinois 60612, United States.
  • Department of Pharmacology & Toxicology, University of Arizona, Tucson, Arizona 85721, United States.

ORCID-Profile: Yangfeng Li, Gregory R J Thatcher, Rui Xiong

Förderung

  • NCRR NIH HHS
  • NIAID NIH HHS
  • Chicago Biomedical Consortium
  • National Institutes of Health
  • G1 Therapeutics

Zitieren

APA

Li, Y., Shen, Z., Ratia, K., Zhao, J., Huang, F., Dubrovyskyii, O., Indukuri, D., Fu, J., Lozano Ramos, O., Thatcher, G. R. J., & Xiong, R. (2024). Structure-Guided Design and Synthesis of Pyridinone-Based Selective Bromodomain and Extra-Terminal Domain (BET)-First Bromodomain (BD1) Inhibitors. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c01837

Vancouver

Li Y, Shen Z, Ratia K, Zhao J, Huang F, Dubrovyskyii O, et al. Structure-Guided Design and Synthesis of Pyridinone-Based Selective Bromodomain and Extra-Terminal Domain (BET)-First Bromodomain (BD1) Inhibitors. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.3c01837

BibTeX
@article{Li2024,
  author = {Li, Yangfeng and Shen, Zhengnan and Ratia, Kiira and Zhao, Jiong and Huang, Fei and Dubrovyskyii, Oleksii and Indukuri, Divakar and Fu, Jiqiang and Lozano Ramos, Omar and Thatcher, Gregory R J and Xiong, Rui},
  title = {Structure-Guided Design and Synthesis of Pyridinone-Based Selective Bromodomain and Extra-Terminal Domain (BET)-First Bromodomain (BD1) Inhibitors},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  doi = {10.1021/acs.jmedchem.3c01837}
}
Kostenlos starten →